Guideline-concordant therapy for community-onset pneumonia considering risk factors for drug-resistant pathogens: a
Yosuke Fukuda1, Naruhito Oda2, Tasuku Honda2
1Department of Medicine, Division of Respiratory Medicine, Yamanashi Red Cross Hospital, 6663-1 Funatsu, Fujikawaguchiko-machi, Yamanashi, Japan. yosukefukuda.showa@gmail.com.
Purpose:
Guideline-concordant therapy (GCT) has been associated with improved outcomes in patients with community-onset pneumonia. However, the impact of GCT remains unclear when the risk of drug-resistant pathogens, such as methicillin-resistant Staphylococcus aureus and Pseudomonas aeruginosa, is considered.
Methods:
We retrospectively evaluated the safety and efficacy of GCT for hospitalised adult patients with community-onset pneumonia at a 270-bed community hospital in Yamanashi, Japan, between January 1, 2020, and May 31, 2025. GCT was defined according to adult pneumonia guidelines issued by the Japanese Respiratory Society 2024 (JRS 2024). Patients were matched one-to-one using propensity score matching. The primary endpoint was 28-day mortality. The study was approved by the Yamanashi Red Cross Hospital Ethics Committee (approval number: 7 - 2, approval date: 01/September/2025).
Results:
Of the 540 eligible patients, 380 were included in the matched analysis. The Kaplan-Meier curve for 28-day mortality showed no statistically significant difference between the GCT group and the non-GCT group (hazard ratio, 1.02; 95% CI, 0.82-1.27, P = 0.94).
Conclusion:
In this single-center observational cohort of patients with community-onset pneumonia, GCT according to the JRS 2024 guideline was not associated with lower 28-day mortality than non-GCT. These findings should be interpreted cautiously in light of the observational study design, the clinical heterogeneity of the cohort, and the potential for residual confounding. Further studies are needed to evaluate the effectiveness of JRS 2024-based treatment strategies in broader clinical settings.
Related Concept Videos
01:29Pneumonia I: Introduction
01:30Pneumonia I: Introduction
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
01:14Atypical Pneumonia
01:28Pulmonary Tuberculosis V
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the progression...
01:28Pneumonia IV: Management
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
01:30Pneumonia V: Nursing management and Prevention
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed.